Intellipharmaceutics International
Toronto
About Intellipharmaceutics International
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. Intellipharmaceutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received U.S. Food and Drug Administration ("FDA") approval) in various stages of development. The Company has abbreviated new drug application ("ANDA") and new drug application ("NDA") 505(b)(2) drug product candidates in its development pipeline.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $19.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2021)
- Ticker: tsx:IPCI
- Website: intellipharmaceutics.com
- Phone: 416-798-3001
Industries & Categories
Biotechnology, Health Care, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/intellipharmaceutics-international-2238370 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.